Drugs in Dev. Infections and Infectious Diseases
Undisclosed
Sweden 
Lead Product(s) : Erdosteine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recipharm’s Proprietary Molecule Erdosteine has been Positively Tested As Part of COVID-19 Treatment
Details : The study indicates that patients taking Erdosteine after hospital discharge benefit significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is one of the first to report HRQoL details in patients with COVID...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2020
Lead Product(s) : Erdosteine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyxone Plans to Initiate a Phase 2 Clinical Trial with Rabeximod in Covid-19 Patients
Details : Cyxone plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients. The treatment is intended to reduce the risk of developing severe respiratory symptoms caused by virus-related overactivation of the immune system.
Product Name : Rob 803
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
